Komori
K

KNC Laboratories Co.,Ltd.

6568Information and Communications, Services and OthersMicro cap
1,266JPY+2.8%
★ Watch (sign-up required)
Price history
¥1,266Latest+14.0%
Drag across the chart to measure the move between two points.Delayed 15 minutes · monthly closing basis
Business overview

The Company’s principal business is providing research, development and production solutions for organic chemicals. It supplies samples and products for customers’ research, development and production activities related to product development and sales, and provides services to resolve various issues in line with each customer’s development stage. The organic chemicals covered are functional chemicals and their intermediates used in fields including pharmaceuticals and information electronics, manufactured from general-purpose chemicals as raw materials. Research and development of chemicals proceeds through a cycle of predicting the chemical structure of a compound with the required functions, actually synthesizing it and evaluating its functions. If the required functions are not obtained, the structure is reconsidered and the process is repeated. Functional evaluation requires proprietary evaluation techniques for each product, such as pharmaceuticals, agrochemicals and dyes. Synthesis itself also involves research, including devising methods for synthesizing the specified compounds and evaluating their purity, yield and cost-effectiveness. Through collaboration between product development companies and the Company, the Company seeks to shorten research and development periods and improve the efficiency of product development. As products progress from research and development to mass production, the Company proposes solutions to manufacturing issues and countermeasures in preparation for mass production after market launch. As customers’ product development progresses from research and development to mass production, the Company provides solutions accordingly. The Company operates in a single business segment: the organic chemical research, development and production solutions business.

Recurring subjects
No threads yetThis company's filings have not been read yet. We are adding them progressively.
Companies sharing a theme
Loading
Key numbersShowing 8 of 20
PER
240.23How many years of earnings it would take to buy the stock. The market average is generally considered to be around 15.
PBR
0.7How many times the company's net assets? Around 1x is generally considered a benchmark.
ROE
0.3%Earning power. A figure above 10% is generally considered good.
Dividend yield
0.0%The annual dividend as a percentage of the share price.
Market capitalization
¥9.8bnShare price × number of shares. The value of the entire company.
Equity ratio
66.4%The proportion of assets funded by money that does not have to be repaid.
Operating margin
2.4%The percentage of revenue remaining from the company’s core business.
Revenue growth (3 years)
6.0%The average annual growth in sales over the past three years.
What to watch next
Expansion of pharmaceutical manufacturing equipment at the Izumo First Plant, scheduled for completion in June 2026, and confirmation of initial start-up results
From June 2026 onward, with the impact on utilization and orders/shipments expected over several quarters after completionImpact MediumLikelihood Medium
Pharmaceutical active pharmaceutical ingredient (API) manufacturing equipment at the KNC Bio Research Center, scheduled for completion in July 2025, followed by verification that operations have become established
During 2026, as the impact of operational stabilization and improvements in utilization and productivity is reflected in the financial resultsImpact MediumLikelihood Medium
Disclosure of progress in the mass-production sales ratio, utilization and bottleneck removal supporting expansion of the mass-production stage to above 60%
From 2026 onward, in line with earnings results and progress disclosuresImpact HighLikelihood Medium
What to watch next
Loading
Who owns itTop holders total 121.2%
Listed holders 121.2%Everyone else 0.0%
Total60.59%
KNC興産(株)19.53%
Miyauchi Hitoshi (宮内 仁志)10.50%
広瀬 克利9.35%
(公財)KNC広瀬財団9.04%
純正化學(株)3.10%
池谷 誠一2.86%
岩見 好爲2.04%
3 other listed holders4.17%
Who owns it
HolderOwnership (%)
Total60.59
KNC興産(株)19.53
Miyauchi Hitoshi (宮内 仁志)10.50
広瀬 克利9.35
(公財)KNC広瀬財団9.04
純正化學(株)3.10
池谷 誠一2.86
岩見 好爲2.04
3 other listed holders4.17
This company's documents
Timely disclosures